Welcome to our dedicated page for Inmed Pharmaceuticals news (Ticker: INM), a resource for investors and traders seeking the latest updates and insights on Inmed Pharmaceuticals stock.
InMed Pharmaceuticals Inc. reports developments as a pharmaceutical company developing proprietary small-molecule drug candidates for diseases with high unmet medical needs. Its pipeline targets CB1 and CB2 receptors and includes INM-901 for Alzheimer's disease, along with ocular and dermatological programs.
Recurring updates cover financial results, business progress, preclinical and regulatory disclosures, shareholder voting matters, capital actions, Nasdaq listing compliance, and changes affecting BayMedica, its wholly owned subsidiary historically associated with rare cannabinoid commercial activities.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
InMed Pharmaceuticals reported a robust financial position with $11.5 million in cash as of December 31, 2022, reflecting a year-over-year increase. The company is nearing the enrollment completion of its Phase 2 clinical trial for Epidermolysis Bullosa, targeting 20 patients. Revenue from its BayMedica segment surged to $0.8 million, a 198% increase compared to the previous fiscal year, driven by enhanced marketing efforts. The net loss for the six months ending December 31, 2022, was reduced to $5.6 million from $7.3 million in the same period last year, indicating improved operational efficiency. InMed aims to leverage its strong cash reserves to achieve critical milestones in 2023.